Molecular therapy for Inflammatory bowel disease: TCTP (Translationally-controlled tumor protein) promotes NFKB-p50/p65 dimer formation, induces inflammatory gene expression downstream of RelA/p65, inhibits colonic pathogenesis, and stalls the progression of inflammatory bowel disease and colitis via down regulation of its target gene, 12/June/2017, 12.11 am

Natural product therapy for middle aged TIIDM patients: Sulforphane, isolated from Broccoli sprouts, decreases DNA-PK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 12/June/2017, 12.06 am
June 11, 2017
Natural product-derived regenerative therapy for muscular atrophy: Oleanolic acid, isolated from olive oil, and Syzygium spp among others, increases the expression of IGF-1, PI3K(p85a) and B-Myb, decreases the expression of tumor suppressors, promotes regeneration of muscle cells, and reverses muscle atrophy via up regulation of its target gene, 12/June/2017, 11.34 pm
June 12, 2017
Show all

Introduction: What they say:

A study from the Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg, University of Mainz, Obere Zahlbarer Str, Mainz, Germany shows that increased levels of Bcl-3 inhibits Treg development and function and thereby promotes spontaneous colitis. This study was published, in the 28 April 2017 issue of the journal “Nature communications”, by Prof. Nadine Hövelmeyer, Sonja Reißig and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Molecular therapy for Inflammatory bowel disease: TCTP (Translationally-controlled tumor protein)  promotes NFKB-p50/p65 dimer formation, induces inflammatory gene expression downstream of RelA/p65, inhibits colonic pathogenesis, and stalls the progression of inflammatory bowel disease and colitis via down regulation of its target gene, 12/June/2017, 12.11 am


What is known?

Prof. Nadine Hövelmeyer’s research team has recently shown that: (1) Bcl-3 is overexpressed in patients with inflammatory bowel disease (IBD); (2) T-cell specific overexpression of Bcl-3 results in spontaneous colitis, inhibition of NFKB function, and decreased Foxp3,  IL-10, CTLA-4, GITR and IL-2R expression; (3) increased expression of Bcl-3 inhibits Treg (regulatory T) cell development and function and expansion of γd T-cells; and (4) increased expression of Bcl-3 promotes gut inflammation and severe colitis, suggesting that Bcl-3 inhibitors may be used to inhibit the progression of inflammatory bowel disease and colitis.


From Significance of the study to Public health relevance:

Given that: (1) Colitis affects 10-12 people/100, 000/annum in the US; (2) about 1 million people suffer from inflammatory bowel disease, characterized by infiltration of T-cells that damage colon, in the US, while in Europe it is 2.5 million; (3) inflammatory bowel disease is more common in westernized nations, including North america and Europe, and in industrialized countries; (4) the incidence of colitis and inflammatory bowel disease is on the rise globally, (5) molecular pathways involved and the mechanism of development of colitis and inflammatory bowel disease is far from understood; (6) substantial amount is spent each year globally for the treatment of colitis and inflammatory bowel disease, there is an urgent need to find: (i) a way to cure colitis and inflammatory bowel disease; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free-Natural product-based drug that permanently cures, not just treats, colitis and inflammatory bowel disease.


From Research Findings to Therapeutic opportunity:

This study suggests a natural product-based therapy for inflammatory bowel disease and colitis.

TCTP (Translationally-controlled tumor protein), by regulating the expression of its target genes, it may: (1) increase DNA binding of p50/p50 and p50/p65 NF-KB dimers, and thereby promote NFKB function; (2) increase the expression of inflammatory genes that function down stream of NFKB; (3) increase the expression of Foxp3, IL-10, CTLA-4, GITR and IL-2R; (4) promote Treg cell development; (5) inhibit colonic pathogenesis; (6) inhibit the progression of inflammatory bowel disease and colitis.

Figure 1. Mechanistic insights into how TCTP inhibits inflammatory bowel disease and colitis.

Together, pharmacological formulations encompassing “TCTP activators or their analogues, either alone or in combination with other drugs”, may be used to treat inflammatory bowel disease and colitis.


Details of the research findings:

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How TCTP activates p50/p65-NFKB to inhibit the progression of inflammatory bowel disease and colitis

Amount: $500

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L.,  Molecular therapy for Inflammatory bowel disease: TCTP (Translationally-controlled tumor protein)  promotes NFKB-p50/p65 dimer formation, induces inflammatory gene expression downstream of RelA/p65, inhibits colonic pathogenesis, and stalls the progression of inflammatory bowel disease and colitis via down regulation of its target gene, 12/June/2017, 12.11 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.